LRMR - Cash Flow Statement - Larimar Therapeutics, Inc.

Millions

	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017	Dec-2016	Dec-2015	Dec-2014	Dec-2013	Dec-2012	Dec-2011
OPERATING CASH FLOW
Net Income	(36.9)	(35.4)	(50.6)	(42.5)	(23.1)	(61.4)	(52.0)	(57.9)	(74.3)	(36.5)	(14.0)	(13.9)	(13.2)
Depreciation & Amortization	0.3	0.3	0.3	0.2	78 K	0.3	0.2	0.2	70 K	16 K	12 K	11 K	4 K
Deferred Income Tax	0	0	0	0	3.6	(9.6)	0	0	(8.6)	(0.8)	0	0	0
Stock Based Compensation	7.6	6.6	5.5	2.2	0.1	0.2	0	0	8.6	1.6	0	0	0
Other Operating Activities	(1.9)	(0.8)	15 K	10 K	(3.6)	9.8	9.1	10.6	9.1	6.7	0.6	0.2	78 K
Change in Working Capital	(2.5)	1.7	2.7	(2.0)	0.2	0.6	99 K	(5.5)	6.7	0.8	(1.6)	62 K	0.8
Cash From Operations	(33.5)	(27.6)	(42.1)	(42.2)	(22.7)	(51.5)	(43.8)	(52.0)	(59.6)	(28.2)	(15.0)	(13.6)	(12.3)
INVESTING CASH FLOW
Capital Expenditures	(0.2)	100 K	(0.3)	62 K	83 K	(0.1)	55 K	(0.7)	(0.6)	58 K	17 K	2 K	35 K
Other Items	33.5	(90.9)	24.5	17.2	0	(6.8)	35.7	52.1	(91.5)	(57.3)	0	0	10 K
Cash From Investing Activities	33.4	(91.0)	24.2	17.1	83 K	(6.9)	35.6	51.4	(92.1)	(57.3)	17 K	2 K	45 K
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	67.2	0.2	0.2	131.0	0	0	0	0
Total Debt Repaid	0	0	0	0	0	0	16.4	(2.9)	(1.4)	7.3	0	6.0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Financing Activities	30 K	0	0	18.0	19.4	0	0	0	0	0	0	13 K	0
Cash From Financing Activities	30 K	75.3	19.9	93.6	19.4	66.9	16.6	(2.7)	129.2	108.1	40.6	22.1	10.1
CHANGE IN CASH
Net Change In Cash	76 K	(43.3)	1.9	68.5	(3.4)	8.6	8.4	(3.2)	(22.5)	22.6	0	0	0
FREE CASH FLOW
Free Cash Flow	(33.6)	(27.7)	(42.4)	(42.3)	(22.8)	(51.6)	(43.8)	(52.6)	(60.1)	(28.3)	(15.0)	(13.6)	(12.3)

Free